SUN Pharmaceutical IND L

NSE: SUNPHARMA · Pharmaceuticals · sector

₹1,740.00NSE close 2026-10-26

Key numbers

Market cap₹4,17,478 cr

Price₹1,740.00

52w high / low₹2,047 / ₹1,584

P/E34.5xSector median 27.9x

P/B5.0xSector median 2.9x

Book value₹348.3

Dividend yield0.94%Sector median 0.48%

ROE15.5%Sector median 11.7%

ROCE18.7%Sector median 12.3%

OPM28.6%Sector median 14.0%

Debt / equity0.05xSector median 0.16x

EV/EBITDA22.7xSector median 18.6x

Interest cover45.1x

Current ratio2.82x

Sales growth 3y+10.0%Sector median +9.6%

Profit growth 3y+10.7%Sector median +13.3%

PEG3.25x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹32,537 cr vs borrowings ₹4,082 cr (FY26): cash is higher (net cash).
Operating profit covered interest 45.1x in the last 12 months.
0.01% of the promoters' shares are pledged (0.0% of all shares).
Promoter holding fell by 1.80 percentage points in a year, to 52.68% (2026-09-30).
Operating cash flow was below net profit in 1 of the last 5 years (FY23).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 18% of net profit in the last 12 months.
Debtor days went from 85 (FY24) to 97 (FY26).
Dividend paid in 5 of the last 5 financial years.
Price ₹1,740.00 on 2026-10-26: -15.0% from the 52-week high, +9.9% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,989.90 · low ₹1,582.30

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	13,291	13,675	12,959	13,851	14,478	15,521	14,612	15,300
EBITDA	3,939	3,693	3,354	3,484	4,527	4,459	3,954	4,214
OPM %	29.6%	27.0%	25.9%	25.2%	31.3%	28.7%	27.1%	27.5%
Other income	354	466	613	464	470	579	458	724
Net profit	3,040	2,903	2,150	2,279	3,118	3,369	2,714	2,895
EPS (₹)	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10
Revenue YoY					+8.9%	+13.5%	+12.8%	+10.5%
Profit YoY					+2.6%	+16.0%	+26.2%	+27.0%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	38,654	43,886	48,497	52,578	58,462	59,911
EBITDA	5,831	11,475	12,529	14,594	16,424	17,154
Net profit	3,273	8,474	9,576	10,929	11,479	12,096
EPS (₹)	13.60	35.30	39.90	45.60	47.80	50.40
Revenue growth		+13.5%	+10.5%	+8.4%	+11.2%	+11.4%
Profit growth		+158.9%	+13.0%	+14.1%	+5.0%	+16.6%
Dividend / share (₹)	9.00	10.50	12.50	15.50	16.50

Compounded growth	3 years	5 years	Last 12 months
Sales	+10.0%	+11.8%	+11.4%
Net profit	+10.6%	+31.6%	+16.6%
EPS	+10.6%	+31.6%	–
Share price	–	-4.1% (2y)	+3.2%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	55,995	63,667	72,218	83,570
Borrowings	–	6,198	2,846	1,870	4,082
Cash & equivalents	–	15,143	19,105	24,988	32,537
Total assets	–	80,744	85,463	92,101	1,08,785
Fixed assets	–	10,390	10,192	10,036	11,114
Capital work in progress	–	963	1,108	1,234	1,381
Investments	–	5,068	5,999	4,249	3,789
Receivables	–	11,439	11,249	13,046	15,510
Inventory	–	10,513	9,868	10,243	11,493
Payables	–	5,682	5,653	6,184	7,334

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	8,985	4,959	12,135	14,072	12,419
Cash from investing	-5,725	-7,944	-690	-5,306	-11,344
Cash from financing	-5,193	2,376	-6,710	-7,906	-2,513
Capex	1,495	2,086	2,202	2,129	3,609
Free cash flow	7,490	2,874	9,933	11,944	8,810

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	15.1%	15.0%	15.1%	13.7%
ROCE %	–	15.4%	17.0%	18.9%	17.6%
Debtor days	–	95	85	91	97
Inventory days	–	360	338	348	363
Payable days	–	194	194	210	232
Cash conversion cycle (days)	–	261	229	229	228
Working capital days	–	166	199	239	257

Shareholding

Holder	% (2026-09-30)
Promoters	52.68%
FIIs	14.36%
DIIs	22.27%
of which Mutual funds	13.01%
of which Insurance	6.80%
Government	0.00%
Public (non-institutions)	10.70%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	52.68%

Promoter group	%
Shanghvi Finance Private Limited	40.30%
Dilip.S.Shanghvi	9.60%
Aditya Medisales Limited	1.67%
Unimed Investments Limited	0.43%
Vibha Dilip Shanghvi	0.37%
Aalok Dilip Shanghvi	0.12%
Vidhi Dilip Shanghvi	0.12%
Shanghvi Family & Friends Benefit Trust	0.05%
Kumud Shantilal Shanghvi	0.00%
Flamboyawer Finance Private Limited	0.00%
Shanghvi Universal Private Limited (Formerly known as Sanghvi Properties Private Limited)	0.00%
Sun Petro Private Limited (Formerly known as Gujarat Sun Pharmaceutical Industries Private Limited)	0.00%

Public holders above 1%	%
Life Insurance Corporation Of India	5.32%
Icici Prudential Value Fund	3.21%
Sbi Nifty 50 Etf	2.82%
Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I	1.96%
Nippon Life India Trustee Ltd-A/C Nippon India Etf Nifty 50 Bees	1.32%
Raksha Sudhir Valia	1.20%
Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund	1.14%
Lakshdeep Investments & Finance (P) Ltd.	1.02%
Government Pension Fund Global	1.01%

7,14,266 shareholders. Pledged: 0.01% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
LUPIN	₹89,616 cr	16.2x	4.0x	27.9%	27.9%	30.0%	+18.9%	0.61%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-07	Dividend	Dividend - Rs 5 Per Share
2026-02-05	Dividend	Interim Dividend - Rs 11 Per Share
2025-07-07	Dividend	Dividend - Rs 5.50 Per Share
2025-02-06	Dividend	Interim Dividend - Rs 10.50 Per Share
2024-07-12	Dividend	Dividend - Rs 5 Per Share
2024-02-09	Dividend	Interim Dividend - Rs 8.50 Per Share
2023-07-28	Dividend	Dividend - Rs 4 Per Share
2023-02-08	Dividend	Interim Dividend - Rs 7.50 Per Share
2022-08-19	Dividend	Dividend - Rs 3 Per Share
2022-02-09	Dividend	Interim Dividend - Rs 7 Per Share
2021-08-23	Dividend	Annual General Meeting/Dividend - Rs 2 Per Share
2021-02-09	Dividend	Interim Dividend - Rs 5.50 Per Share
2020-08-19	Dividend	Annual General Meeting/Dividend - Re 1 Per Share
2020-02-17	Dividend	Interim Dividend - Rs 3 Per Share
2019-08-20	Dividend	Annual General Meeting/Dividend - Rs 2.75 Per Share
2018-09-17	Dividend	Annual General Meeting/Dividend Rs 2 Per Share
2017-09-18	Dividend	Annual General Meeting/Dividend - Rs 3.50 Per Share
2016-09-08	Dividend	Annual General Meeting/Dividend Re 1/- Per Share
2016-07-14	Buyback	Buy Back
2015-10-21	Dividend	Annual General Meeting/ Dividend - Rs 3/- Per Share

Documents

Links go to the original files on the exchange website.

About the company

Pharmaceutical: Manufacturing and marketing of pharmaceutical products


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	SUNPHARMA
BSE code	524715
ISIN	INE044A01036
Face value	₹1.0
Incorporated	1993-03-01
Website	www.sunpharma.com
Plants (India / abroad)	17 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.